

Are you currently being treated
for **ROS1+** NSCLC, and
planning for the next step
in your treatment journey?

NVL-520 is an investigational therapy that targets ROS1 and is specifically designed to potentially overcome some of the challenges that can limit currently available treatments.

Talk to your doctor today to find out whether you or a loved one may be eligible to receive NVL-520 through the ARROS-1 clinical trial.

ARROS-1 is open and enrolling. For more information, visit www.clinicaltrials.gov (NCT05118789), or reach out to medical@nuvalent.com.

ARROS-1 |  Nuvalent



PRECISELY
^ Targeted Therapies for patients with cancer



A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangements

ClinicalTrials.gov identifier: NCT05118789

Eligible Patients

- ✓ Age \geq 18 years old (*for Phase 1 portion only*)
- ✓ Any advanced solid tumor, including Non-Small Cell Lung Cancer (NSCLC)
- ✓ Test positive for a ROS1 rearrangement
- ✓ Must have prior anticancer treatment (*for Phase 1 portion only*)

ROS1 Targeted Therapies

Tumor cells that are “ROS1-positive” (ROS1+) carry changes in the ROS1 gene, identified through cancer genomic testing.

Certain genomic alterations like ROS1 rearrangements can drive tumor growth and survival. These are known as “driver alterations” and are critical targets for cancer therapy.

NVL-520 is designed with the goal of inhibiting ROS1 even in the presence of mutations that enable resistance to other therapies.

Cancer Genomic Testing

Identifying your tumor’s specific driver alterations can help your doctor design a matched precision treatment plan for you.

If you have been diagnosed with NSCLC or another solid tumor and are not sure if your tumor has been genomically tested, ask your doctor today about testing options available to you.